Gesynta Pharma AB announced the dosing of the first patient in its Phase 2 clinical trial (NOVA) for vipoglanstat, a new non-hormonal, non-opioid drug candidate for treating endometriosis. This trial aims to evaluate the efficacy and safety of vipoglanstat in managing endometriosis-related pain and other symptoms in around 190 women aged 18 to 45 across several European countries. The trial will compare two doses of vipoglanstat with a placebo over approximately four menstrual cycles, with results expected in 2027. Vipoglanstat targets the enzyme mPGES-1, which is involved in producing the inflammatory mediator PGE2 in endometriotic lesions. Preclinical studies have shown that vipoglanstat can reduce pain and lesion load, and previous clinical studies have confirmed its safety and tolerability. Endometriosis is a chronic inflammatory condition affecting around 10% of women of reproductive age and is associated with significant pain and infertility. Gesynta Pharma's research on targeting mPGES-1 originated at Karolinska Institutet in Sweden, and the company is also developing another candidate, GS-073, for chronic inflammatory pain.

Gesynta Pharma AB, a clinical-stage pharmaceutical company in Stockholm, Sweden, announced the formation of a Scientific Advisory Board (SAB) to guide the clinical development of vipoglanstat, a non-hormonal, non-opioid treatment for endometriosis currently in Phase 2 trials. The SAB includes four experts in women's health: Dr. Linda C. Giudice, Dr. Christian Becker, Dr. Sawsan As-Sanie, and Dr. Marie-Madeleine Dolmans, each with significant experience in endometriosis research and treatment. Gesynta Pharma is developing vipoglanstat as a selective mPGES-1 inhibitor, aiming to offer a new treatment option for endometriosis, a chronic condition affecting 10% of women of reproductive age. The company is also preparing another drug candidate, GS-073, for Phase 1 trials targeting chronic inflammatory pain.

Gesynta Pharma AB has announced that its Phase 2 clinical trial application for vipoglanstat, a treatment for endometriosis, has been approved by UK authorities. The trial, named NOVA, will assess the efficacy and safety of vipoglanstat compared to a placebo in about 190 patients across Europe. The UK Medicines and Healthcare products Regulatory Agency and Research Ethics Committee have approved the study, allowing it to proceed. Vipoglanstat is a non-hormonal, non-opioid drug targeting the enzyme mPGES-1, which is involved in endometriosis. The trial aims to provide critical dosage information for future development. Gesynta Pharma is a Swedish company focused on innovative treatments for inflammatory diseases, and its research originated from Karolinska Institutet. The company is also developing another drug candidate, GS-073, for chronic inflammatory pain.

Gesynta Pharma AB, a clinical-stage pharmaceutical company based in Sweden, has raised an additional SEK 43 million in its Series B second closing, bringing the total to SEK 347 million. This funding round saw new investments from HealthCap and Hadean Growth Fund, led by Innovestor Life Science. The funds will support the Phase 3 program preparation for vipoglanstat, a drug aimed at treating endometriosis, a condition affecting 190 million women worldwide. Gesynta Pharma has also strengthened its board with the addition of Kristina Ekberg from HealthCap, and independent directors Cristina Csimma and David Colpman. Vipoglanstat is a non-hormonal, non-opioid treatment targeting the enzyme mPGES-1, showing promise in reducing pain and lesions in endometriosis. A Phase 2 clinical trial involving 190 patients across Europe is planned for 2025. The company's shareholders include Nordic, European, and US investors.

Gesynta Pharma AB, a clinical-stage pharmaceutical company, has appointed Eva Johnsson as its new Chief Medical Officer and Vice President of Clinical Development. Eva Johnsson, who has extensive experience in clinical drug development and medical affairs, previously worked at Grünenthal and AstraZeneca R&D. She is also an associate professor at the University of Gothenburg. Gesynta Pharma is preparing a Phase II clinical trial for vipoglanstat, a new treatment for endometriosis, a chronic inflammatory disease affecting women. The trial will involve around 190 patients across Europe. Patric Stenberg, CEO of Gesynta Pharma, expressed confidence in Eva's ability to enhance the company's clinical development capabilities. As Eva Johnsson takes on her new role, Charlotte Edenius will transition to a strategic position as VP R&D Strategy. Gesynta Pharma focuses on developing treatments targeting the enzyme mPGES-1, with vipoglanstat being their lead compound. The company is also preparing GS-073 for clinical trials for chronic inflammatory pain. Gesynta Pharma's shareholders include Hadean Ventures, Industrifonden, and Innovestor Life Science.

Gesynta Pharma AB has secured SEK 304 million in a Series B financing round led by Innovestor Life Science. The funds will support a Phase II clinical trial of vipoglanstat, a non-hormonal drug candidate for treating endometriosis, a chronic inflammatory disease affecting 190 million women worldwide. The trial aims to address the inadequacies of current treatments, which often have significant side effects. The financing attracted new European and U.S. investors and existing shareholders. The trial will enroll about 190 patients to evaluate the drug's efficacy and safety. Gesynta Pharma's research focuses on targeting mPGES-1, an enzyme involved in inflammatory processes. The company also plans to develop another drug candidate, GS-073, for chronic inflammatory pain.